Deutsche Bank AG Buys 7,495 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL)

Deutsche Bank AG boosted its stake in Castle Biosciences, Inc. (NASDAQ:CSTL) by 12.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 67,667 shares of the company’s stock after buying an additional 7,495 shares during the quarter. Deutsche Bank AG owned approximately 0.24% of Castle Biosciences worth $1,803,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of CSTL. Centiva Capital LP boosted its stake in shares of Castle Biosciences by 18.8% in the 4th quarter. Centiva Capital LP now owns 23,015 shares of the company’s stock valued at $613,000 after purchasing an additional 3,647 shares in the last quarter. Captrust Financial Advisors lifted its holdings in Castle Biosciences by 2,567.5% during the 4th quarter. Captrust Financial Advisors now owns 215,322 shares of the company’s stock valued at $5,738,000 after purchasing an additional 207,250 shares during the last quarter. Bank of America Corp DE boosted its position in Castle Biosciences by 100.0% in the fourth quarter. Bank of America Corp DE now owns 403,553 shares of the company’s stock valued at $10,755,000 after buying an additional 201,806 shares in the last quarter. BNP Paribas Financial Markets bought a new stake in Castle Biosciences during the fourth quarter worth about $6,639,000. Finally, Algert Global LLC grew its stake in Castle Biosciences by 11.3% during the fourth quarter. Algert Global LLC now owns 149,491 shares of the company’s stock worth $3,984,000 after buying an additional 15,170 shares during the last quarter. 92.60% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Castle Biosciences

In other news, insider Derek J. Maetzold sold 1,236 shares of Castle Biosciences stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $21.52, for a total transaction of $26,598.72. Following the completion of the sale, the insider now owns 74,627 shares in the company, valued at $1,605,973.04. The trade was a 1.63% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In the last three months, insiders have sold 27,454 shares of company stock worth $553,030. Company insiders own 6.50% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. Lake Street Capital cut their target price on shares of Castle Biosciences from $40.00 to $35.00 and set a “buy” rating for the company in a research note on Tuesday, May 6th. Canaccord Genuity Group cut their price objective on Castle Biosciences from $42.00 to $37.00 and set a “buy” rating for the company in a research report on Tuesday, May 6th. Robert W. Baird increased their target price on Castle Biosciences from $36.00 to $37.00 and gave the stock an “outperform” rating in a report on Friday, February 28th. Guggenheim set a $30.00 target price on Castle Biosciences and gave the company a “buy” rating in a research note on Friday, March 28th. Finally, Scotiabank reduced their price target on shares of Castle Biosciences from $44.00 to $40.00 and set a “sector outperform” rating on the stock in a research report on Wednesday. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $37.00.

Castle Biosciences Stock Up 1.3%

Shares of CSTL opened at $16.10 on Friday. The business’s fifty day moving average price is $19.14 and its two-hundred day moving average price is $24.53. The firm has a market capitalization of $464.84 million, a price-to-earnings ratio of 80.50 and a beta of 1.19. Castle Biosciences, Inc. has a 52 week low of $15.66 and a 52 week high of $35.84. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.64 and a current ratio of 7.78.

Castle Biosciences (NASDAQ:CSTL) last issued its quarterly earnings results on Monday, May 5th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.12). The firm had revenue of $87.99 million for the quarter, compared to analyst estimates of $80.40 million. Castle Biosciences had a net margin of 1.95% and a return on equity of 1.47%. On average, analysts predict that Castle Biosciences, Inc. will post 0.44 earnings per share for the current year.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.